Key result
Combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent adverse outcomes like sudden cardiac death and cardiovascular mortality in chronic heart failure.
Why the study?
Does combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors prevent adverse outcomes in chronic heart failure?
Does combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors prevent adverse outcomes in chronic heart failure?
Preliminary evidence suggests that combining phosphodiesterase inhibitors with beta-blockers may prevent the adverse mortality outcomes seen with phosphodiesterase inhibitors alone in heart failure.
Should not yet change practice in chronic HF; leaves open prospective validation of PDEi plus beta-blocker combinations.
Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent these adverse outcomes. Compartmentation of cyclic adenosine 3',5'-monophosphate signaling may prove critical in determining myocardial response to combination therapy.
No takes yet. Share an insight, caveat, or question.
Tassell et al. (2008) conducted a review in Chronic Heart Failure. Combination therapy with β-adrenergic receptor antagonists and phosphodiesterase inhibitors was evaluated. Combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent adverse outcomes like sudden cardiac death and cardiovascular mortality in chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: